These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 34700119)

  • 21. The pharmaceutical industry as a medicines provider.
    Henry D; Lexchin J
    Lancet; 2002 Nov; 360(9345):1590-5. PubMed ID: 12443614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
    Roughead EE; Kim DS; Ong B; Kemp-Casey A
    WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How do patents and economic policies affect access to essential medicines in developing countries?
    Attaran A
    Health Aff (Millwood); 2004; 23(3):155-66. PubMed ID: 15160813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
    Assefa Y; Hill PS; Ulikpan A; Williams OD
    Global Health; 2017 Sep; 13(1):73. PubMed ID: 28903757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Effects of Intellectual Property Rights on Access to Medicines and Catastrophic Expenditure.
    Jung Y; Kwon S
    Int J Health Serv; 2015; 45(3):507-29. PubMed ID: 26077858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Affordability of adult HIV/AIDS treatment in developing countries: modelling price determinants for a better insight of the market functioning.
    Sagaon-Teyssier L; Singh S; Dongmo-Nguimfack B; Moatti JP
    J Int AIDS Soc; 2016; 19(1):20619. PubMed ID: 27765142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A method for understanding generic procurement of HIV medicines by developing countries with patent protection.
    Beall RF; Attaran A
    Soc Sci Med; 2017 Jul; 185():118-126. PubMed ID: 28578209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does the market share of generic medicines influence the price level?: a European analysis.
    Dylst P; Simoens S
    Pharmacoeconomics; 2011 Oct; 29(10):875-82. PubMed ID: 21797288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of the legal regime of intellectual property protection in the pharmaceutical market.
    Pashkov VM; Golovanova IA; Olefir AA
    Wiad Lek; 2016; 69(3 pt 2):582-586. PubMed ID: 27717949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patent challenges in the procurement and supply of generic new essential medicines and lessons from HIV in the southern African development community (SADC) region.
    't Hoen EFM; Kujinga T; Boulet P
    J Pharm Policy Pract; 2018; 11():31. PubMed ID: 30524732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Availability, pricing and affordability of selected medicines for noncommunicable diseases.
    Heidari E; Varmaghani M; Abdollahiasl A
    East Mediterr Health J; 2019 Oct; 25(7):473-480. PubMed ID: 31612979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Compulsory Licensing of Pharmaceuticals in High-Income Countries: A Comparative Analysis.
    Qunaj L; Kaltenboeck A; Bach PB
    Milbank Q; 2022 Mar; 100(1):284-313. PubMed ID: 35257415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology.
    Saeed A; Saeed H; Saleem Z; Fang Y; Babar ZU
    PLoS One; 2019; 14(4):e0216122. PubMed ID: 31022276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intellectual property rights, market competition and access to affordable antiretrovirals.
    Pascual F
    Antivir Ther; 2014; 19 Suppl 3():57-67. PubMed ID: 25309984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prices, availability and affordability of medicines in Rwanda.
    Bizimana T; Kayumba PC; Heide L
    PLoS One; 2020; 15(8):e0236411. PubMed ID: 32745100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature.
    Ocran Mattila P; Ahmad R; Hasan SS; Babar ZU
    Front Public Health; 2021; 9():628744. PubMed ID: 33996712
    [No Abstract]   [Full Text] [Related]  

  • 39. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries.
    Waning B; Diedrichsen E; Moon S
    J Int AIDS Soc; 2010 Sep; 13():35. PubMed ID: 20840741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Voluntary licensing of long-acting HIV prevention and treatment regimens: using a proven collaboration- and competition-based mechanism to rapidly expand at-scale, sustainable, quality-assured and affordable supplies in LMICs.
    Gaayeb L; Das A; James I; Murthy R; Nobre S; Burrone E; Morin S
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26092. PubMed ID: 37439078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.